Anavex Life Sciences Corp (AVXL)

[polarbear77]

amateur, you confusingly said "but they removed MS from trial indications in 10-k which is most authentic and legal document - co does not want to give wrong indications and mislead investors. That removal is telling a different story"

I've personally read through the most recent annual fiscal year 10-k from 9/30/16 as well as two subsequent 10-q quarterlies and I CANNOT find any mention of the Multiple Sclerosis indication in any of the Anavex SEC 10-k or 10-q reports.

So please explain your assertion to the board that they removed the MS indication from their 10-k. How could they remove it if it wasn't there to begin with?

Not surprisingly I believe that you are blatantly wrong.

If someone can show me that they have previously listed MS as a target indication for their compounds and then subsequently REMOVED it, then I'll remove this post.

amateur, surely you are not interested in misleading actual investors here, are you?


10-q quarterly for 6/30/17
http://secfilings.nasdaq.com/filingFrameset.asp?FilingID=12216537&RcvdDate=8/7/2017&CoName=ANAVEX%20LIFE%20SCIENCES%20CORP.&FormType=10-Q&View=html

10-q quarterly for 12/31/16
http://secfilings.nasdaq.com/filingFrameset.asp?FilingID=11830127&RcvdDate=2/7/2017&CoName=ANAVEX%20LIFE%20SCIENCES%20CORP.&FormType=10-Q&View=html

10-k Annual fiscal year 9/30/16
http://secfilings.nasdaq.com/filingFrameset.asp?FilingID=11735980&RcvdDate=12/14/2016&CoName=ANAVEX%20LIFE%20SCIENCES%20CORP.&FormType=10-K&View=html